1. Home
  2. LSAK vs RVMDW Comparison

LSAK vs RVMDW Comparison

Compare LSAK & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • RVMDW
  • Stock Information
  • Founded
  • LSAK 1997
  • RVMDW N/A
  • Country
  • LSAK South Africa
  • RVMDW United States
  • Employees
  • LSAK N/A
  • RVMDW 490
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • RVMDW
  • Sector
  • LSAK Finance
  • RVMDW
  • Exchange
  • LSAK Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • LSAK N/A
  • RVMDW N/A
  • IPO Year
  • LSAK N/A
  • RVMDW N/A
  • Fundamental
  • Price
  • LSAK $5.06
  • RVMDW $0.24
  • Analyst Decision
  • LSAK
  • RVMDW
  • Analyst Count
  • LSAK 0
  • RVMDW 0
  • Target Price
  • LSAK N/A
  • RVMDW N/A
  • AVG Volume (30 Days)
  • LSAK 28.5K
  • RVMDW N/A
  • Earning Date
  • LSAK 02-05-2025
  • RVMDW N/A
  • Dividend Yield
  • LSAK N/A
  • RVMDW N/A
  • EPS Growth
  • LSAK N/A
  • RVMDW N/A
  • EPS
  • LSAK N/A
  • RVMDW N/A
  • Revenue
  • LSAK $573,679,000.00
  • RVMDW N/A
  • Revenue This Year
  • LSAK $5.12
  • RVMDW N/A
  • Revenue Next Year
  • LSAK $12.55
  • RVMDW N/A
  • P/E Ratio
  • LSAK N/A
  • RVMDW N/A
  • Revenue Growth
  • LSAK 6.38
  • RVMDW N/A
  • 52 Week Low
  • LSAK $3.00
  • RVMDW N/A
  • 52 Week High
  • LSAK $5.60
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 39.59
  • RVMDW N/A
  • Support Level
  • LSAK $4.67
  • RVMDW N/A
  • Resistance Level
  • LSAK $5.39
  • RVMDW N/A
  • Average True Range (ATR)
  • LSAK 0.22
  • RVMDW 0.00
  • MACD
  • LSAK -0.04
  • RVMDW 0.00
  • Stochastic Oscillator
  • LSAK 42.39
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: